Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care - PubMed (original) (raw)
Review
Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care
Merle Diamond et al. Am J Med. 2005 Mar.
Abstract
Migraine is a chronic, intermittently disabling condition that affects physical, mental, and social aspects of health-related quality of life. Because patients seeking assistance with migraine most often present to primary care providers, these healthcare professionals play critical roles in the diagnosis and treatment process. A comprehensive migraine management plan involves a partnership between the patient and healthcare professional where treatment goals and strategies are established. Elements of such a plan should include preventive strategies to reduce the frequency and effects of future attacks as well as the use of acute treatments to address the immediate need for relief during an attack. Approaches to prevention include education, lifestyle modification, and, often, appropriate medication. Many medications have been used for acute treatment. Nonspecific agents include nonsteroidal anti-inflammatory drugs (NSAIDs), single or combination analgesics (sometimes including antiemetics or caffeine), and narcotics. Migraine-specific medications include ergot alkaloids and triptans (5-hydroxytryptamine(1B/1D) agonists). Various professional organizations have created guidelines to help providers in choosing appropriate management interventions. Clinical approaches to the patient with migraine include step care, whereby all patients begin on a simple or nonspecific treatment, stepping up to the next level of therapy if treatment is unsuccessful; or stratified care, whereby first-line therapy is tailored to the severity of the patient's pattern of headache. Studies have demonstrated that for more disabled headache patients, the stratified-care approach results in more robust headache response with less disability and greater cost-effectiveness than step care. Patient satisfaction studies demonstrate that the use of migraine-specific abortive medications (triptans) is associated with a higher satisfaction rate than over-the-counter preparations, NSAIDs, and analgesic combinations. Patients who initially reported satisfaction with the latter medications also reported a preference for triptan therapy. Healthcare professionals can assist patients, not only by choosing the most appropriate medication but also by assessing whether the level of benefit the patient is currently receiving could be improved.
Similar articles
- Optimizing migraine therapy: evidence-based and patient-centered care.
Diamond ML, Wenzel RG, Nissan GR. Diamond ML, et al. Expert Rev Neurother. 2006 Jun;6(6):911-9. doi: 10.1586/14737175.6.6.911. Expert Rev Neurother. 2006. PMID: 16784413 Review. - Acute management of migraine.
Chowdhury D. Chowdhury D. J Assoc Physicians India. 2010 Apr;58 Suppl:21-5. J Assoc Physicians India. 2010. PMID: 21049703 - Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness.
Ceballos Hernansanz MA, Sanchez Roy R, Cano Orgaz A, López-Gil A; START 10 Study Group. Ceballos Hernansanz MA, et al. Clin Ther. 2003 Jul;25(7):2053-69. doi: 10.1016/s0149-2918(03)80204-7. Clin Ther. 2003. PMID: 12946550 Clinical Trial. - Evaluating the safety and tolerability profile of acute treatments for migraine.
Martin VT, Goldstein JA. Martin VT, et al. Am J Med. 2005 Mar;118 Suppl 1:36S-44S. doi: 10.1016/j.amjmed.2005.01.018. Am J Med. 2005. PMID: 15841886 Review. - Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
Blumenfeld A, Gennings C, Cady R. Blumenfeld A, et al. Headache. 2012 Apr;52(4):636-47. doi: 10.1111/j.1526-4610.2011.02058.x. Epub 2012 Jan 6. Headache. 2012. PMID: 22221151 Review.
Cited by
- Increased GABA+ in People With Migraine, Headache, and Pain Conditions- A Potential Marker of Pain.
Peek AL, Leaver AM, Foster S, Oeltzschner G, Puts NA, Galloway G, Sterling M, Ng K, Refshauge K, Aguila MR, Rebbeck T. Peek AL, et al. J Pain. 2021 Dec;22(12):1631-1645. doi: 10.1016/j.jpain.2021.06.005. Epub 2021 Jun 25. J Pain. 2021. PMID: 34182103 Free PMC article. - A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States.
Harris L, L'Italien G, O'Connell T, Hasan Z, Hutchinson S, Lucas S. Harris L, et al. Adv Ther. 2021 Oct;38(10):5087-5097. doi: 10.1007/s12325-021-01781-z. Epub 2021 May 31. Adv Ther. 2021. PMID: 34057676 Free PMC article. Review. - An Evaluation of Medication Prescribing Patterns for Acute Migraine in the Emergency Department: A Scoping Review.
Lim JH, Karimi L, Wijeratne T. Lim JH, et al. J Clin Med. 2021 Mar 12;10(6):1191. doi: 10.3390/jcm10061191. J Clin Med. 2021. PMID: 33809194 Free PMC article. Review. - Lifestyle modifications as therapy for medication refractory post-traumatic headache (PTHA) in the military population of Okinawa.
Baker VB, Eliasen KM, Hack NK. Baker VB, et al. J Headache Pain. 2018 Nov 22;19(1):113. doi: 10.1186/s10194-018-0943-2. J Headache Pain. 2018. PMID: 30466384 Free PMC article. Clinical Trial. - Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial.
Holroyd KA, Cottrell CK, O'Donnell FJ, Cordingley GE, Drew JB, Carlson BW, Himawan L. Holroyd KA, et al. BMJ. 2010 Sep 29;341:c4871. doi: 10.1136/bmj.c4871. BMJ. 2010. PMID: 20880898 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical